Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis
- PMID: 28935570
- DOI: 10.1016/j.ajpath.2017.08.021
Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis
Abstract
Nuclear factor-erythroid 2-related factor-2 (Nrf2) is a master regulator of the antioxidant response. However, studies in models of Friedreich ataxia, a neurodegenerative and cardiodegenerative disease associated with oxidative stress, reported decreased Nrf2 expression attributable to unknown mechanisms. Using a mouse conditional frataxin knockout (KO) model in the heart and skeletal muscle, we examined the Nrf2 pathway in these tissues. Frataxin KO results in fatal cardiomyopathy, whereas skeletal muscle was asymptomatic. In the KO heart, protein oxidation and a decreased glutathione/oxidized glutathione ratio were observed, but the opposite was found in skeletal muscle. Decreased total and nuclear Nrf2 and increased levels of its inhibitor, Kelch-like ECH-associated protein 1, were evident in the KO heart, but not in skeletal muscle. Moreover, a mechanism involving activation of the nuclear Nrf2 export/degradation machinery via glycogen synthase kinase-3β (Gsk3β) signaling was demonstrated in the KO heart. This process involved the following: i) increased Gsk3β activation, ii) β-transducin repeat containing E3 ubiquitin protein ligase nuclear accumulation, and iii) Fyn phosphorylation. A corresponding decrease in Nrf2-DNA-binding activity and a general decrease in Nrf2-target mRNA were observed in KO hearts. Paradoxically, protein levels of some Nrf2 antioxidant targets were significantly increased in KO mice. Collectively, cardiac frataxin deficiency reduces Nrf2 levels via two potential mechanisms: increased levels of cytosolic Kelch-like ECH-associated protein 1 and activation of Gsk3β signaling, which decreases nuclear Nrf2. These findings are in contrast to the frataxin-deficient skeletal muscle, where Nrf2 was not decreased.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response.Redox Biol. 2024 Oct;76:103339. doi: 10.1016/j.redox.2024.103339. Epub 2024 Sep 4. Redox Biol. 2024. PMID: 39243573 Free PMC article.
-
Treatment of dilated cardiomyopathy in a mouse model of Friedreich's ataxia using N-acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis.Pharmacol Res. 2020 Sep;159:104994. doi: 10.1016/j.phrs.2020.104994. Epub 2020 Jun 10. Pharmacol Res. 2020. PMID: 32534099
-
GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition.Redox Biol. 2019 Sep;26:101275. doi: 10.1016/j.redox.2019.101275. Epub 2019 Jul 17. Redox Biol. 2019. PMID: 31349118 Free PMC article.
-
Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich's ataxia.Free Radic Biol Med. 2020 Nov 1;159:177-188. doi: 10.1016/j.freeradbiomed.2020.07.019. Epub 2020 Jul 30. Free Radic Biol Med. 2020. PMID: 32739593 Review.
-
Shaping the Nrf2-ARE-related pathways in Alzheimer's and Parkinson's diseases.Ageing Res Rev. 2019 Sep;54:100942. doi: 10.1016/j.arr.2019.100942. Epub 2019 Aug 12. Ageing Res Rev. 2019. PMID: 31415806 Review.
Cited by
-
An Overview of the Ferroptosis Hallmarks in Friedreich's Ataxia.Biomolecules. 2020 Oct 28;10(11):1489. doi: 10.3390/biom10111489. Biomolecules. 2020. PMID: 33126466 Free PMC article. Review.
-
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).Ann Neurol. 2021 Feb;89(2):212-225. doi: 10.1002/ana.25934. Epub 2020 Nov 5. Ann Neurol. 2021. PMID: 33068037 Free PMC article. Clinical Trial.
-
Emerging antioxidant therapies in Friedreich's ataxia.Front Pharmacol. 2024 Feb 6;15:1359618. doi: 10.3389/fphar.2024.1359618. eCollection 2024. Front Pharmacol. 2024. PMID: 38379897 Free PMC article. Review.
-
Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement.Biomolecules. 2020 May 1;10(5):702. doi: 10.3390/biom10050702. Biomolecules. 2020. PMID: 32369911 Free PMC article. Review.
-
The Role of Fucoxanthin as a Potent Nrf2 Activator via Akt/GSK-3β/Fyn Axis against Amyloid-β Peptide-Induced Oxidative Damage.Antioxidants (Basel). 2023 Mar 3;12(3):629. doi: 10.3390/antiox12030629. Antioxidants (Basel). 2023. PMID: 36978877 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous